Loading stock data…
Microbot Medical Inc. (MBOT)
$1.87+0.10 (+5.65%)
Market ClosedLast close Jun 29
Microbot Medical Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Microbot Medical Inc. in the Healthcare sector is trading at $1.87 with a market capitalization of $132M. Wall Street consensus targets $7.00 (3 analysts), implying a +274.3% move over the next 12 months. The stock is currently near its 52-week low of $1.60, remaining 18.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +274.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $105,000 | $0 | $0 | $0 | $0 |
| Gross Profit | $2,000 | — | — | — | $0 |
| Operating Income | -$4.32M↓ | -$4.14M↓ | -$3.86M↓ | -$3.72M↓ | -$3.02M |
| Net Income | -$3.67M↓ | -$3.46M↑ | -$3.58M↓ | -$3.50M↓ | -$2.60M |
Peer Comparison
JNJUNHPFE
Fundamentals
Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical sy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$132.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-19.18%
Volume
Today's trading volume
910,729
Recent News
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)
Microbot Medical (MBOT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Microbot Medical (NASDAQ:MBOT) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue Estimates
Microbot Medical (MBOT) delivered earnings and revenue surprises of +37.50% and -76.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
XRAY heads into Q1 earnings with U.S. softness, tariff pressure and transformation costs weighing on margins as investors watch for signs of stabilization.
Can Strong Growth Aid INNV's Q3 Earnings Amid Margin Seasonality?
InnovAge heads into fiscal Q3 earnings with strong growth momentum and margin gains, but seasonal cost pressures and fading Medicaid tailwinds may temper near-term upside.